Patents by Inventor Thomas F. Bumol

Thomas F. Bumol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5732717
    Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: March 31, 1998
    Assignee: Eli Lilly and Company
    Inventors: August M. Watanabe, Thomas F. Bumol, Mitchell I. Steinberg, Mary J. Kallman, Kurt Rasmussen
  • Patent number: 5686467
    Abstract: A method of inhibiting imperfect tissue repair or a physiological condition due at least in part thereto comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: November 11, 1997
    Assignee: Eli Lilly and Company
    Inventors: Thomas F. Bumol, George J. Cullinan
  • Patent number: 5597726
    Abstract: The present invention relates to a naturally occurring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of patients with coronary artery disease. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: January 28, 1997
    Assignee: Eli Lilly and Company
    Inventors: Thomas F. Bumol, Leslie M. McEvoy
  • Patent number: 5580774
    Abstract: The present invention discloses novel chimeric monoclonal antibodies, directed against proteoglycans of human melanoma cells, having antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: December 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Lisa S. Beavers, Thomas F. Bumol, Robert A. Gadski
  • Patent number: 5574047
    Abstract: A method of inhibiting imperfect tissue repair or a physiological condition due at least in part thereto comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: November 12, 1996
    Assignee: Eli Lilly and Company
    Inventors: Thomas F. Bumol, George J. Cullinan
  • Patent number: 5348887
    Abstract: The present invention comprises novel recombinant DNA compounds which encode the .about.40,000 dalton adenocarcinoma antigen recognized by monoclonal antibody KS 1/4. Eukaryotic and prokaryotic expression vectors have been constructed that comprise novel KSA-encoding DNA and drive expression of KSA when transformed into an appropriate host cell. The novel expression vectors can be used to produce KSA derivatives, such as non-glycosylated KSA, and to produce KSA precursors, such as nascent KSA, and to produce subfragments of KSA. The recombinant-produced KSA is useful for the diagnosis, prognosis and treatment of disease states including adenocarcinomas of the lung, prostate, breast, ovary and colon/rectum; and for the creation of novel antibodies for treatment or diagnosis of the above.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: September 20, 1994
    Assignee: Eli Lilly and Company
    Inventors: Thomas F. Bumol, Robert A. Gadski, Amy E. Hamilton, J. Richard Sportsiman, Joann Strnad
  • Patent number: 5196324
    Abstract: The present invention relates to a naturally occurring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of patients with coronary artery disease. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the inveniton, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease.
    Type: Grant
    Filed: October 17, 1990
    Date of Patent: March 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: Thomas F. Bumol, Leslie M. McEvoy
  • Patent number: 4975369
    Abstract: The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.
    Type: Grant
    Filed: April 21, 1988
    Date of Patent: December 4, 1990
    Assignee: Eli Lilly and Company
    Inventors: Lisa S. Beavers, Thomas F. Bumol, Robert A. Gadski, Barbara J. Weigel